Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
2.88
Dollar change
-0.02
Percentage change
-0.69
%
Index- P/E- EPS (ttm)-7.45 Insider Own1.95% Shs Outstand1.36M Perf Week-4.64%
Market Cap3.90M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.33M Perf Month-2.37%
Income-9.13M PEG- EPS next Q- Inst Own1.88% Short Float0.41% Perf Quarter0.70%
Sales0.00M P/S- EPS this Y- Inst Trans-4.27% Short Ratio0.23 Perf Half Y-31.43%
Book/sh9.44 P/B0.30 EPS next Y- ROA-29.78% Short Interest0.01M Perf Year-53.90%
Cash/sh16.30 P/C0.18 EPS next 5Y- ROE-41.57% 52W Range2.32 - 8.77 Perf YTD-57.63%
Dividend Est.- P/FCF- EPS past 5Y8.59% ROI-71.34% 52W High-67.18% Beta1.40
Dividend TTM- Quick Ratio65.36 Sales past 5Y0.00% Gross Margin- 52W Low24.14% ATR (14)0.24
Dividend Ex-Date- Current Ratio65.36 EPS Y/Y TTM71.73% Oper. Margin- RSI (14)50.06 Volatility9.01% 8.94%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price14.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-442.81% Payout- Rel Volume0.03 Prev Close2.90
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsAug 02 Avg Volume24.10K Price2.88
SMA204.19% SMA50-2.12% SMA200-26.54% Trades Volume803 Change-0.69%
Sep-11-24 09:00AM
Aug-16-24 09:52PM
Jul-18-24 09:00AM
Jun-26-24 09:00AM
May-20-24 11:54AM
09:00AM Loading…
May-07-24 09:00AM
Apr-24-24 09:15AM
Apr-09-24 09:15AM
Apr-03-24 08:00AM
Dec-19-23 09:00AM
Dec-06-23 09:00AM
Nov-02-23 09:00AM
Sep-26-23 09:00AM
Sep-07-23 09:00AM
Jul-19-23 09:00AM
09:00AM Loading…
Jul-13-23 09:00AM
Mar-07-23 09:00AM
Dec-16-22 09:00AM
Nov-18-22 09:00AM
Oct-19-22 09:00AM
Sep-28-22 11:50AM
Aug-12-22 09:00AM
Jul-26-22 09:15AM
Jul-21-22 09:15AM
Jul-20-22 09:15AM
May-17-22 09:15AM
Apr-19-22 09:15AM
Apr-05-22 09:15AM
Mar-29-22 09:15AM
Mar-22-22 09:15AM
09:15AM Loading…
Mar-15-22 09:15AM
Feb-23-22 09:15AM
Feb-07-22 09:38AM
Feb-01-22 09:15AM
Dec-06-21 11:58AM
Sep-28-21 09:00AM
Sep-10-21 09:00AM
Aug-05-21 10:00AM
Jul-26-21 09:15AM
Jul-21-21 09:00AM
Jul-14-21 09:00AM
Jul-07-21 09:00AM
Jun-24-21 09:00AM
Jun-14-21 09:00AM
Jun-09-21 09:00AM
05:38AM
May-19-21 09:00AM
May-10-21 09:00AM
Apr-26-21 09:00AM
Apr-01-21 09:00AM
Mar-05-21 09:00AM
Feb-25-21 09:12AM
Feb-12-21 09:00AM
Feb-09-21 09:00AM
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.